What does the evidence say about Coq10 Blood Pressure Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Coq10 Blood Pressure Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Background/objectives Oxidized low-density lipoprotein (oxLDL) has emerged as a promising biomarker of oxidative burden and cardiovascular risk. [Leaovitavat R (2026); evidence level 2] - Conclusions Daily ubiquinol (100 mg/day) for 12 weeks was associated with a significant within-group decrease in plasma oxLDL among prediabetic participants; however, the between-group difference versus placebo was not significant. [Leaovitavat R (2026); evidence level 2] - This study is aimed at evaluating the effect of ubiquinol supplementation, a potent lipophilic antioxidant, on oxLDL levels in prediabetic patients. [Leaovitavat R (2026); evidence level 2] - 3 Elevated intraocular pressure (IOP) remains the only proven modifiable risk factor and the principal target of all current pharmacological and surgical interventions. [Hanyuda Akiko (2026); evidence level 3] - Evidence from human ocular samples and animal models consistently demonstrates ROS accumulation and oxidative biomarker elevation across all anatomical compartments relevant to glaucoma: the trabecular meshwork (TM), the optic nerve head (ONH), and the RGC layer [,]. [Hanyuda Akiko (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.